tbuckley/cabot-search huggingface dataset:
Something to sing about: A global choir of cancer survivors—Building bridges.
Authors: Paul P. Donnellan, Donal Gill, Deanna Hynes, Olive Gallagher, Seamus Leonard
Journal: Journal of Clinical Oncology (2013)

e20505 Background: 68% of cancer patients live at least 5 years after diagnosis and many are cured. Cancer survivors continue to need support. Music is energising, affirming and therapeutic. More funds are needed for cancer research so that more patients become long-term survivors. In 2012 Galway University Hospital founded 'Something To Sing About' (STSA.ie), a not-for-profit organisation to support cancer survivors and cancer research. Methods: Local publicity brings small bands of cancer survivors together rehearsing the same music at the same time every week (Wednesday 7pm) in a local hall, hospital or hotel, each with its own local musical director. The music is selected by a representative music committee and music therapist. Musical instruction is disseminated by the chief musical director via website and social media. A plenary rehearsal takes place every 3 months. All profits from events and music sales are allocated to cancer research projects through an open peer-reviewed grant-application process. Results: In 6 months STSA has grown from concept to network of 20 centres with total membership of 251 cancer-survivors. Immediate feedback has been extremely positive as assessed by personal communication and facebook activity (currently 1,025 ‘likes'). Over 100 singing-survivors participated in the first plenary rehearsal. All commercial venues have donated their meeting rooms gratis. Internationally there is one participating centre in Brisbane, Australia, with others signalling their intention to join in 2013 including: Memorial Sloan Kettering Cancer Center, New York; 14 breast cancer support centres in UK; and one centre in the Czech Republic (updated at meeting). STSA members are particularly keen on establishing links with other cancer patients abroad. Professional musicians are pledging support and suggesting fund-raising collaborations. Conclusions: Cancer survivors continue to need ongoing support and find the music therapy and group therapy provided by STSA most beneficial. Cancer survivors are very interested in supporting cancer research. STSA has the potential to become a major international cancer support network and cancer research foundation.
LEAFLET THICKENING OR IMMOBILITY IN TRANSCATHETER OR SURGICAL AORTIC VALVES: RESULTS FROM THE EVOLUT LOW RISK LTI SUBSTUDY
Authors: Jonathon Leipsic, Philipp Blanke, Michael Reardon, G. Michael Deeb, Steven J. Yakubov, Jeffrey J. Popma
Journal: Journal of the American College of Cardiology (2020)
A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma
Authors: Sabna Rajeev Krishnan, Gabriele De Rubis, Hayley Suen, Douglas Joshua, Yiu Lam Kwan, Mary Bebawy
Journal: Blood Cancer Journal (2020)

Abstract Multiple myeloma is an incurable cancer of bone marrow plasma cells, with a 5-year survival rate of 43%. Its incidence has increased by 126% since 1990. Treatment typically involves high-dose combination chemotherapy, but therapeutic response and patient survival are unpredictable and highly variable—attributed largely to the development of multidrug resistance (MDR). MDR is the simultaneous cross-resistance to a range of unrelated chemotherapeutic agents and is associated with poor prognosis and survival. Currently, no clinical procedures allow for a direct, continuous monitoring of MDR. We identified circulating large extracellular vesicles (specifically microparticles (MPs)) that can be used to monitor disease burden, disease progression and development of MDR in myeloma. These MPs differ phenotypically in the expression of four protein biomarkers: a plasma-cell marker (CD138), the MDR protein, P-glycoprotein (P-gp), the stem-cell marker (CD34); and phosphatidylserine (PS), an MP marker and mediator of cancer spread. Elevated levels of P-gp + and PS + MPs correlate with disease progression and treatment unresponsiveness. Furthermore, P-gp, PS and CD34 are predominantly expressed in CD138 − MPs in advanced disease. In particular, a dual-positive (CD138 − P-gp + CD34 + ) population is elevated in aggressive/unresponsive disease. Our test provides a personalised liquid biopsy with potential to address the unmet clinical need of monitoring MDR and treatment failure in myeloma.
A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH ON DEVELOPMENT OF CONTRAST INDUCED NEPHROPATHY IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Muhammad J. Ahsan, Saad Ullah Malik, Omar Kousa, Hafiz Muhammad Fazeel, Nisma Javed, Sidra Tahseen, Azka Latif, Mydah Hashmi, Kashif Shaikh, Venkata Andukuri, Mark Holmberg
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF AGEING ON THE FUNCTIONAL EVALUATION OF INTERMEDIATE CORONARY STENOSES WITH ADENOSINE-BASED FRACTIONAL FLOW RESERVE (FFR) AND INSTANTANEOUS WAVE-FREE RATIO (IFR)
Authors: Monica Verdoia, Rocco Gioscia, Matteo Nardin, Federica Negro, Francesco Tonon, Harry Suryapranata, Elvin Kedhi, Marco Marcolongo, Giuseppe De Luca
Journal: Journal of the American College of Cardiology (2020)
N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome.
Authors: Ning Shan, Irina Alho, Margarida Matias, Mariana Faria, Sandra Casimiro, Arlindo Ferreira, Kim Leitzel, Suhail M. Ali, Allan Lipton, Luis Costa
Journal: Journal of Clinical Oncology (2013)

9634 Background: The bone resorption marker NTX at baseline is a prognostic marker in BC patients with BM treated with zoledronic acid (ZOL), Coleman RE, JCO 2005. We investigate how the response of urinary NTX levels during ZOL therapy is related to patient outcome and disease characteristics. Methods: Consecutive BC patients with BM were prospectively included if they received monthly intravenous ZOL. Urinary NTX was determined at baseline and at following 1, 3, 6, 9 and 12 months from the initial ZOL treatment. NTX levels were considered elevated if &gt; 50 nmol/mmol creatinine. The NTX changes were compared with patient and disease characteristics. Relative risks for negative clinical outcomes were estimated with Cox regression models. Results: Seventy-one BC patients with BM, mean aged 61.4 (29-87), were included. Mean survival was 34.1 months (3-131), with 21 patients alive after the last follow up (median 29 months). Thirty-nine patients also had extraskeletal metastases (BM-E+). Totally 329 urinary NTX samples were evaluated. At baseline, mean NTX was 153.0 (15.4 – 700.7) and 78.9% had elevated levels. Mean baseline NTX increased with age: 71.2 (&lt;40); 139.3 (50-59); 241.8 (70-79). Among patients with normal NTX at 3 months, 89.5% continued to show normal NTX at 12 months. After ZOL treatments, 46.9%, 54.7%, and 61.0% of patients had normal NTX at 3, 6 and 12 months, respectively. NTX variance (1-12 months) was higher for BM-E+ patients compared with BM-only patients, p&lt;0.001. Risk factor of death for patients with persistent elevated NTX at 3 months was 1.74 (p=0.074). Age and BM-E+ were also associated with risk of death. There was a trend to shorter survival in BC-E+ patients (p=0.056). Majority of patients (88.2%) with longer survival (&gt; 36 months) and younger (age &lt; 60) received endocrine therapy. Conclusions: Early (3 months) urinary NTX normalization to ZOL correlates with long-term NTX normalization and survival. BC-E+ patients have a reduced NTX normalization rate compared to BM-only patients and may deserve further investigation for a more adequate schedule of bone-targeting agents.
COMPARISON OF CLINICAL OUTCOMES OF PATIENTS UNDERGOING EDWARDS SAPIEN VS. EDWARDS SAPIEN 3 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
Authors: Srilakshmi Vallabhaneni, Marsel Matka, Purujit Thacker, Matthew Carey, Raymond Durkin, Christopher Sarnoski, Jamshid Shirani
Journal: Journal of the American College of Cardiology (2020)
Two distinct ubiquitin-binding motifs in A20 mediate its anti-inflammatory and cell-protective activities
Authors: Arne Martens, Dario Priem, Esther Hoste, Jessica Vetters, Sofie Rennen, Leen Catrysse, Sofie Voet, Laura Deelen, Mozes Sze, Hanna Vikkula, Karolina Slowicka, Tino Hochepied, Kalliopi Iliaki, Andy Wullaert, Sophie Janssens, Mohamed Lamkanfi, Rudi Beyaert, Marietta Armaka, Mathieu J. M. Bertrand, Geert van Loo
Journal: Nature Immunology (2020)
PREDICTORS OF CLINICAL SUPER-RESPONDERS IN THE COAPT TRIAL
Authors: Paul A. Grayburn, Anna Sannino, David J. Cohen, Saibal Kar, None Kar, Scott Lim, Jacob M. Mishell, Brian Whisenant, Michael Rinaldi, Samir R. Kapadia, Vivek Rajagopal, Aaron Crowley, JoAnn Lindenfeld, William Abraham, Michael Mack, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
Maternal nutrition and child respiratory outcomes: paradigms of lung health and disease
Authors: Corrine Hanson, Emily Brigham
Journal: European Respiratory Journal (2020)

Given the large public health burden of obstructive lung diseases, such as asthma and COPD, considerable research has been conducted to identify targeted interventional strategies, with nutrition and dietary intake receiving increasing amounts of attention. Diets rich in antioxidants and omega-3 fatty acids, and low in saturated fats and processed foods ( i.e. the Mediterranean diet) have been proposed as “respiratory healthy” diets, possibly attenuating the inflammatory response and potentially protecting against disease incidence, prevalence, and morbidity [1–5]. A new study shows diet during pregnancy may influence lung health in future generations <http://bit.ly/2FEOhlS>
Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).
Authors: Ruth O'Regan, Mustafa Ozguroglu, Fabrice Andre, Masakazu Toi, Guy Heinrich Maria Jerusalem, Sharon Wilks, Claudine Isaacs, Binghe Xu, Norikazu Masuda, Francis P. Arena, Denise Aysel Yardley, Yoon Sim Yap, Pabak Mukhopadhyay, Shyanne Douma, Mona El-Hashimy, Tanya Taran, Tarek Sahmoud, David Edward Lebwohl, Luca Gianni
Journal: Journal of Clinical Oncology (2013)

505 Background: Everolimus (EVE) is an inhibitor of mammalian target of rapamycin (mTOR), a protein kinase central to a number of signaling pathways regulating cell growth and proliferation. Data from preclinical and phase 1/2 clinical studies indicated that adding EVE to trastuzumab (TRAS) plus chemotherapy may restore sensitivity to and enhance efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapy. The international BOLERO-3 phase 3 study is being conducted to evaluate the addition of EVE to TRAS plus vinorelbine. Methods: Adult women with HER2 + advanced breast cancer and who received prior taxane therapy and experienced recurrence or progression on TRAS were randomized 1:1 to receive either EVE or placebo (5 mg/day) in combination with weekly TRAS and vinorelbine (25 mg/m 2 ). The primary endpoint is progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, safety, quality of life, and pharmacokinetics. Final analysis will be conducted after approximately 417 PFS events. Results: The trial accrued 569 patients between October 2009 and May 2012. Previous therapy included TRAS (100%), a taxane (100%), and lapatinib (28%). The median age was 54 years, and 76% of patients had visceral metastases, 5% had stable brain metastases, 56% had hormone-receptor–positive disease, 33% had Eastern Cooperative Oncology Group performance status of 1 or 2, and 41% had 3 or more metastatic sites. The median number of prior chemotherapy lines in the metastatic setting was 1. As of February 4, 2013, a total of 396 PFS events were reported. Conclusions: Final PFS analysis will be performed in early May 2013; primary and secondary efficacy endpoints will be presented. Clinical trial information: NCT01007942.
AGE DEPENDENT ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION PATIENTS WITH INTERMEDIATE RISK (CHA2DS2 VASC SCORE OF 1 OR 2) OF ISCHEMIC STROKE (A NATIONWIDE POPULATION BASED STUDY)
Authors: Moo Hyun Kim, Kwang Min Lee, Sun Young Choi
Journal: Journal of the American College of Cardiology (2020)
EFFECTS OF 6 WEEKS OF TREATMENT WITH DAPAGLIFLOZIN, A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, ON MYOCARDIAL FUNCTION AND METABOLISM IN TYPE 2 DIABETES PATIENTS: A RANDOMIZED PLACEBO-CONTROLLED STUDY
Authors: Jonas Oldgren, Sanna Laurila, Axel Åkerblom, Aino Latva-Rasku, Eleni Rebelos, Henrik Isackson, Maria Saarenhovi, Olof Eriksson, Kerstin Heurling, Edvin Johansson, Ulrica Wilderäng, Cecilia Karlsson, Russell Esterline, Ele Ferrannini, Jan Oscarsson, Pirjo Nuutila
Journal: Journal of the American College of Cardiology (2020)
In-hospital mortality of patients admitted through the emergency department of a comprehensive cancer center.
Authors: Ahmed F. Elsayem, Carmen E. Gonzalez, S. J. Yeung, Kelly W. Merriman, Knox H. Todd
Journal: Journal of Clinical Oncology (2012)

6125 Background: Cancer is a common presenting condition for emergency departments (EDs); however, there is limited information on outcomes of ED cancer patients subsequently admitted to the hospital. The purpose of this study is to describe outcomes of patients with hematologic malignancies versus those with solid tumors admitted through the ED of a comprehensive cancer center. Methods: We queried the ED database of The University of Texas MD Anderson Cancer Center for calendar year 2010 and linked it to our institutional data warehouse, including tumor registry data. We classified all leukemia and related disorders, lymphoma, multiple myeloma, and bone marrow transplant patients as hematologic malignancies, and remaining cancers as solid tumors. Descriptive statistics, including chi-square, and t-tests were used in two-sided comparisons. All statistical analyses were performed using SPSS version 15. Results: 20,732 total ED visits were made by 9,320 unique cancer patients. Of these, 5,364 (58%) were admitted to the hospital at least once (range 1-13 admits). ED admissions constituted 39% of total unique patients admitted (N=13,753). The main admission indications for solid tumor patients were infectious complications (particularly pneumonia), intractable pain, or dehydration. For hematologic malignancies, the main indication was neutropenic fever. 211/1656 (13%) of liquid tumor patients were admitted to the Intensive Care Unit (ICU) compared to 484/3708 (13%) of solid tumor patients (P=NS). Of all patients admitted through the ED, 587/5364 (10.9%) died during hospitalization. The hematologic hospital mortality rate was 225/1653 (13.6%) versus 362/3708 (9.8%) for solid tumors (P&lt;0.001). Only 242/8389 (3%) of patients admitted directly from outpatient clinics died during the hospitalization (p&lt;0.001). Conclusions: Patients admitted through the ED, particularly those with hematologic malignancies, have a high hospital mortality rate. ED-based palliative care interventions may be justified to improve quality of life and prevent unnecessary costly interventions and ICU admission. Further research should define predictors of poor outcomes in cancer patients admitted through the ED.
Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data
Authors: Sijian Yu, Fen Huang, Zhiping Fan, Li Xuan, Danian Nie, Yajing Xu, Ting Yang, Shunqing Wang, Zujun Jiang, Na Xu, Ren Lin, Jieyu Ye, Dongjun Lin, Jing Sun, Xiaojun Huang, Yu Wang, Qifa Liu
Journal: Journal of Hematology & Oncology (2020)

Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of haploidentical donor (HID) transplant for refractory acute leukemia need to be further explored. In this study, we compared the outcomes of HID with MSD for refractory acute leukemia.This study population came from two prospective multicenter trials (NCT01883180, NCT02673008). Two hundred and seventy-eight patients with refractory acute leukemia were enrolled in this study, including 119 in HID group and 132 in MSD group. Sequential intensified conditioning was employed in all patients, and donor lymphocyte infusion (DLI) was administered in patients in the absence of active GVHD and according to minimal residual disease (MRD) from day + 60 post-transplantation for preventing relapse.The complete remission of leukemia by day + 30 post-transplant were 94% and 93%, respectively, in HID and MSD groups (p = .802). The 1-year incidence of grades II-IV acute GVHD was 62% and 54% (p = .025), and 3-year incidence of chronic GVHD was 55% and 55% (p = .789), respectively, in two groups. HID transplant had lower incidence of first episode of MRD positivity and relapse than MSD transplant (28% vs 45%, p = .006; 26% vs 38%, p = .034). There was higher infection-related mortality in HID than MSD (8% vs 2%, p = .049) within the first 100 days' post-transplant. The 5-year overall survival was 46% and 42% (p = .832), respectively; the 5-year disease-free survival was 43% and 39% (p = .665), in HID and MSD groups, respectively.HID transplant has lower relapse, but higher infection-related mortality and similar survival rates in refractory acute leukemia by the strategy of sequential intensified conditioning followed by DLI compared with MSD transplant.
Early alterations of microRNA expression to predict and modulate melanoma metastasis.
Authors: Eva Hernando, Douglas Hanniford, Shulian Shang, Miguel F. Segura, Anna C. Pavlick, Russell S. Berman, Richard L. Shapiro, Farbod Darvishian, Iman Osman, Yongzhao Shao
Journal: Journal of Clinical Oncology (2012)

8550 Background: Melanoma is curable for most patients whose tumors are surgically removed early in disease progression; however, many primary melanomas recur and progress to metastasis. Clinical staging is insufficient to robustly classify patients at highest risk of recurrence, and prognostic molecular biomarkers have not yet been identified. Methods: We performed miRNA profiling of 92 FFPE primary melanomas to discover metastasis relevant miRNAs and develop predictive models of recurrence, which were then validated in an independent cohort. We identified miRNAs differentially expressed between primary tumors that did and did not recur (3-year minimum follow-up) and between thick and thin lesions. We selected candidate miRs for screening in a fluorescence-based in vitro invasion assay, and prioritized a subset for in vivo testing. Potential downstream mediators of these miRNAs were selected by mRNA array analysis and tested in a secondary invasion screen. mRNA candidates that mimicked the miR’s invasion-suppressive effect were tested in 3’UTR reporter assays to confirm them as direct targets. Results: Using the discovery cohort we identified a 20 miRNA signature that can distinguish Stage I/II primary tumors (n=70) that did from those did not recur with 3-year minimum follow-up with an AUC=94%, 95% CI: (0.88, 0.99). Applying this model to predict risk for recurrence in the independent validation cohort yielded an AUC = 96%, 95% CI: (0.90, 1) in discriminating recurrent versus non-recurrent stages I/ II patients (n=45). From the discovery cohort, 40 candidates were selected for invasion assay screening, of which 5 miRNAs robustly inhibit in vitro invasion in 5 melanoma cell lines. Three miRs (miR-382, miR-516b, and miR-7) strongly suppressed metastasis in a mouse model. Moreover, multiple mRNAs tested as potential mediators mimicked the invasion-suppressive effects of candidate miRs. Of those, NCAPG2 and CDC42 were identified as miR-516b targets, CTTN as a miR-382 target, and PIK3CD as a miR-7 target. These genes have been linked to metastasis in melanoma or other tumors. Conclusions: Our data demonstrate that aberrant expression of specific miRNAs at diagnosis is predictive of and functionally impacts melanoma progression.
Preclinical and clinical impact of the GLI2 transcription factor in non-small cell lung cancer (NSCLC).
Authors: Ticiana A.B. Leal, Vladimir S. Spiegelman, Srikanta Goswami, Kurt R. Oettel, Tracey L. Weigel, Wei Huang, Sangbum Choi, KyungMann Kim, Martha M. Larson, Tien Hoang, Toby Christopher Campbell, Anne M. Traynor
Journal: Journal of Clinical Oncology (2013)

e18537 Background: Components of the Hedgehog (Hh) signaling pathway are over-expressed in NSCLC. Hh signaling contributes to tumorigenesis in lung cancer and is under investigation as a therapeutic target. We assessed in vitro characteristics of the GLI2 transcription factor, a primary mediator of Hh signaling, in NSCLC tumorigenesis, and its prognostic impact in early stage NSCLC. Methods: Colony formation, growth in soft agar, and measurement of GLI2 RNA were assayed in A549 NSCLC cells. Changes in tumor growth and proliferation were evaluated using a two-sample t-test. The automated quantitative analysis system (AQUA) was used to assess protein expression of GLI2 in NSCLC specimens from 88 deceased patients (pts) with resected stages I and II NSCLC. Pts did not receive additional pre- or post-operative anti-cancer therapies. Pt age, sex, smoking history, histology, TNM stage, and type of resection were also collected. Progression-free survival (PFS) and overall survival (OS) were estimated per Kaplan-Meier; multivariate Cox proportional hazard analyses were used to determine if the GLI2 AQUA score was an independent prognostic factor. Results: GLI2 knockdown in A549 NSCLC cells using GLI2 shRNA resulted in inhibition of colony formation and in the anchorage-independent growth, compared to A549 cells with intact GLI2 function. Characteristics of our population included median age 73 (43-96), males 62.5%, smokers 96%, adenocarcinoma 46.6%, squamous cell histology 40.9%, and stage I 62.5%. GLI2 AQUA score was not associated with any clinical variable per Wilcoxon analyses. High GLI2 AQUA score was associated with shorter PFS (median PFS 8.6 mo [95% CI 7.0-10.7 mo]) compared to low GLI2 AQUA score (median PFS 17.2 mo [95% CI 15.8-22.6 mo], p=0.001), and with shorter OS (median OS 14.8 mo [95% CI 10.5-23.0 mo]), compared to low GLI2 score (median 25.9 mo [95% CI 20.2-35.7 mo], p&lt;0.001), independent of clinical variables. Conclusions: The GLI2 transcription factor of Hh signaling impacts in vitro models of NSCLC tumorigenicity and is an independent negative prognostic factor in early stage disease. Hh signaling remains a worthwhile investigational therapeutic target in NSCLC.